Perficient: Drug Development
SEPTEMBER 19, 2023
jobs by 2028. This solidifies that Salesforce is leading the charge in AI, and Perficient is leaning into the partnership to bring innovative solutions to our clients. We learned about new Salesforce capabilities and technologies, heard new product announcements, and connected with peers and clients from across industries.
Drug Discovery World
SEPTEMBER 26, 2022
According to MarketWatch, the drug repurposing sector was thought to be worth $25,280 in 2021 and is expected to grow to $30,620 million by 2028 with a CAGR of 2.8%. This level of growth is unsurprising for an industry which will always look to the latest opportunities to drive science. . Benefits and barriers .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Agency IQ
MAY 28, 2024
CE mark in addition to its own UKCA mark, with a plan to continue doing so through 2028 or 2030, depending on the legislation to which the CE mark applies. Additionally, companion diagnostics and combination products that contain medicinal substances that haven’t yet been licensed in the U.K. Presently, the U.K. recognizes the E.U.
FDA Law Blog: Biosimilars
DECEMBER 3, 2023
CMS will send the final manufacturer invoice for discount liabilities accrued by then on April 30, 2028. Sunsetting of Coverage Gap Discount Program: The 70% coverage gap discount under the CGDP will continue until December 31, 2024. Final Guidance at 2.
The Pharma Data
NOVEMBER 8, 2020
It is estimated that there will potentially be 13 million moderate-to-severe acne patients treated with oral antibiotics in the urban Chinese population by 2028, which represents a significant opportunity to launch an innovative product whose clinical development is largely de-risked. Guidance for FY 2020.
The Pharma Data
JANUARY 9, 2021
Pipeline progress is expected across the vaccines, therapeutics, and devices portfolios, anticipating at least one Phase 3 launch and one Biologics License Application (BLA)/Emergency Use Authorization (EUA) filing. FOOTNOTES. (1)
The Pharma Data
SEPTEMBER 15, 2020
27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. The results demonstrated that Penta immune responses were robust and noninferior to licensed meningococcal vaccines (MenB and MenACWY) in individuals 10-25 years of age, regardless of prior MenACWY exposure.
Expert insights. Personalized for you.
59 
Let's personalize your content